


Catalog Number: CM06427

产品信息

Catalog Number:
CM06427CAS号:
928672-86-0分子式:
 $C_{48}H_{52}F_2O_{11}S_2$ 主要靶点:
SGLT主要通路:
G蛋白偶联受体分子量:
907.05溶解度:
DMSO:90mg/mL (198.4mM)

靶点活性

mSGLT2/rSGLT2/hSGLT2, in CHO cells: 2/3.7/4.4 nM (IC₅₀)

体外活性

Canagliflozin inhibits Na⁺-dependent 14C-AMG uptake in CHO-hSGLT2 cells, with an IC₅₀ of 4.4±1.2 nM. Similar IC₅₀ values are obtained in CHO-rSGLT2 and CHO-mSGLT2 cells (IC₅₀ = 3.7 and 2.0 nM for rat and mouse SGLT2, respectively). Canagliflozin inhibits 14C-AMG uptake in CHO-hSGLT1 and mSGLT1 cells with IC₅₀ of 684±159 nM and >1,000 nM, respectively[1].

体内活性

Canagliflozin (30 mg/kg treatment for 4 weeks) reduced blood glucose (BG) levels, respiratory exchange ratio, and body weight gain in DIO mice[1]. Canagliflozin (3 mg/kg for 3 weeks) increases urinary glucose excretion (UGE) with no significant change in total food intake compared with that in vehicle-treated rats, leading to a decrease in body weight in ZF rats[1].

描述

Canagliflozin hemihydrate is a drug of the gliflozin class or subtype 2 sodium-glucose transport inhibitors used for the treatment of type 2 diabetes. SGLT2 is responsible for at least 90% of renal glucose reabsorption (SGLT1 being responsible for the remaining 10%). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine, corresponding to 476 kilocalories.

储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years